Phaseline

Companies › Precigen

Precigen: clinical trials, targets and expected readouts

5 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 2, 1 Phase 4; Oncology, Infectious disease; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Zopapogene imadenovec
p53 gene therapy delivered via adenoviral vector
TP53Phase 4Recurrent Respiratory PapillomatosisDec 2027
PRGN-2009
Oncolytic virus expressing human GM-CSF
–Phase 2Cervical CancerNov 2026
PRGN-3005 UltraCAR-T cells
Autologous CAR T cells targeting a protein on tumor cells
–Phase 1Platinum-Resistant Fallopian Tube CarcinomaNov 2028
PRGN-2012
Gene therapy for recurrent respiratory papillomatosis
–Phase 1Recurrent Respiratory Papillomatosis–
PRGN-3006 T Cells
Anti-CD33 chimeric antigen receptor (CAR) T cell therapy
CD33Phase 1Acute Myeloid Leukemia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04724980PRGN-2012Phase 1Recurrent Respiratory PapillomatosisInfectious diseaseJun 2024
NCT03927261PRGN-3006 T CellsPhase 1Acute Myeloid LeukemiaOncologyAug 2024
NCT06157151PRGN-2009Phase 2Cervical CancerOncologyNov 2026
NCT06538480Zopapogene imadenovecPhase 4Recurrent Respiratory PapillomatosisInfectious diseaseDec 2027
NCT03907527PRGN-3005 UltraCAR-T cellsPhase 1Platinum-Resistant Fallopian Tube CarcinomaOncologyNov 2028

From the company's SEC filings

Cash and short-term investments of $51m on 2026-09-30; operating cash outflow about $67m a year; runway about 9 months at that burn, to Jul 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

TP53 (1) CD33 (1)

Companies with the same targets

SynerGene Therapeutics PMV Pharmaceuticals Kartos Therapeutics OSE Immunotherapeutics Changchun GeneScience Pharmaceutical Nutshell Therapeutics (Shanghai) Jacobio Pharmaceuticals Clasp Therapeutics

Companies built like this

GeoVax Bio-Path Holdings PersonGen BioTherapeutics (Suzhou) Hrain Biotechnology Marzieh Ebrahimi

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.